Stock comparison
Arbutus Biopharma
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABUS
Arbutus Biopharma
Market cap
$859.29M
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABUS | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 72B | RMD |
| Benjamin Graham | 43D | 75B | RMD |
| Philip Fisher | 55C | 75B | RMD |
| Peter Lynch | 48D | 58C | RMD |
| Joel Greenblatt | 100A | 47D | ABUS |
| Charlie Munger | 64D | 69B | RMD |
| Terry Smith | 66B | 73B | RMD |
Side-by-side metrics
| Metric | ABUS | RMD |
|---|---|---|
| Market cap | $859.29M | $30.18B |
| P/E (TTM) | 5.1x | 19.6x |
| EV/EBIT | - | 17.1x |
| ROIC (TTM) | 56.72% | 19.63% |
| Gross margin | 99.98% | 61.69% |
| Net margin | 83.95% | 27.44% |
| Revenue CAGR 5y | 6.4% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 17.1x+157%
- Debt / Equity0.0xvs 0.1x+98%
- P/E (TTM)5.1xvs 19.6x+74%
- Net margin83.95%vs 27.44%+67%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $859.29M+97%
- Revenue CAGR 5y12.64%vs 6.4%+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.